
Lijuan Zhang,^a Yu Luo,^a Shanbao Yu,^a and Wei Lu^{a,b*}

^aDepartment of Chemistry, East China Normal University, Shanghai 200062, China ^bInstitute of Drug Discovery and Development, iAIR, East China Normal University, Shanghai 200062, China *E-mail: wlu@chem.ecnu.edu.cn Received February 22, 2011 DOI 10.1002/jhet.967

Published online 26 October 2012 in Wiley Online Library (wileyonlinelibrary.com).



An efficient route for the synthesis of 4-substituted-2-quinolinone-3-carboxylic acid ethyl esters has been developed through Suzuki or Sonogashira reactions. The advantages of the method include high yields, operational simplicity, and suitability for medicinal modification of 4-substituted quinolinones and their derivatives.

J. Heterocyclic Chem., 49, 1254 (2012).

INTRODUCTION

Quinolinones are an important class of heteroaromatic compounds. Because of their wide spectrum of pharmacological applications, much more attention is focused on development of new members [1]. Among them, 4-substituted-2-quinolinone is one of the scaffolds that exhibit various biological activities (Scheme 1). For instance, quinolin-2(1H)-one derivatives **1** were found as potent inducible nitric oxide synthase inhibitors [2], 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones **2** were apoptosis inducers in human cancer cells [3], and 3,4,6-substituted-2-quinolones **3** were considered as FMS kinase inhibitors [4].


Several methods have been reported in the literature for the synthesis of 4-substituted-2-quinolinones [4,5] (Scheme 2). Among them, the general method was that the 4-position substituent on the quinolinone ring was introduced first before the formation of quinolinone ring. However, this method limited the diversity of the 4-position substituent of quinolinone, because the processes were always repeated.

From the medicinal chemistry point of view, an efficient method to fast synthesize diverse 4-substituted-2-quinolinones is still needed. Herein, we described an efficient method to synthesize 4-substituted-2-quinolinone-3-carboxylic acid ethyl esters in good yields. The key step of our approach involves substitution at 4-position of the quinolinone core using Suzuki and Sonogashira reactions.


RESULTS AND DISCUSSION


As shown in Scheme 3, the starting material 11 was initially reacted with ethyl malonyl chloride in the presence of triethylamine to give the intermediate amide. Without purification of the amide, the quinoline ring was formed to generate compound 12 by sodium hydride [6]. Then compound 12 was reacted with phosphoryl chloride to yield the dichloroquinoline 13. Finally, compound 13 was dechlorinated in the presence of sodium acetate and acetic acid to provide the precursor compound 14 [7].

Because of the strong electron deficiency of 4-substituted quinolinones, compound 14 was considered as the substrate to perform Suzuki and Sonogashira reactions (Scheme 4). Several boric acids containing either electron-donating groups or electron-withdrawing groups, such as phenyl boric acid 15a, 4-methoxy-phenyl boric acid 15b, 3-cyano-phenyl boric acid **15c** and 2-allyl-4,4,5,5-tetramethyl-[1,3,2] dioxaborolane 15d were selected to react with compound 14 in the presence of base under nitrogen for several hours. The reactions proceeded smoothly to produce the corresponding compounds 16a-d in 77, 93, 71, 79% yield, respectively. Obviously, 4-methoxy-phenyl boric acid 15b gave the highest yield (93%) compared with phenyl boric acid 15a (77%) and 3-cyano-phenyl boric acid 15c (71%), suggesting that the electron-donating group of phenyl ring had positive influence on the Suzuki reaction. Phenylacetylene 15e and trimethylsilylacetylene 15f were successfully introduced to 4-position of quinolinone ring by Sonogashira reaction in 88 and 56% yield, respectively.



Scheme 3. Reagents and conditions: (a) monoethyl malonate, EDAC; NaH, ethanol. (b) POCl3, reflux. (c) sodium acetate, acetic acid.





In conclusion, we successfully synthesized several 4-substituted quinolinones by Suzuki or Sonogashira reactions. The advantages of the method include high yields, operational simplicity, and suitability for medicinal chemistry of 4-substituted quinolinones and their derivatives.

EXPERIMENTAL

¹HNMR spectra were recorded on a Bruker DRX-500 (500 MHz). ¹³CNMR spectra were obtained on a JNM-EX400 (100 MHz) and a Bruker DRX-500 (125 MHz). All reagents were used directly as obtained commercially, unless otherwise noted.

Typical procedure for 16a–d. A mixture of 4-chloro quinolinone **14** (100 mg, 0.4 mmol), K_2CO_3 (82 mg, 0.6 mmol), Pd (PPh₃)₄ (43 mg, 0.04 mmol), and the corresponding boric acid or boric acid ester **15a–d** (0.6 mmol) in 10 mL toluene and 1 mL water was refluxed at the atmosphere of nitrogen for 3–7 h, monitored by TLC, the solvents were evaporated *in vacuo* and the crude product was purified by column chromatography (ethyl acetate/petroleum ether = 1:1).

2-Oxo-4-phenyl-1,2-dihydroquinoline-3-carboxylic Acid Ethyl Ester 16a. ¹HNMR (CDCl₃): δ 0.96 (t, *J* = 6 Hz, 3H), 4.11 (m, 2H), 7.14 (t, *J* = 8 Hz, 1H), 7.29 (d, *J* = 8 Hz, 1H), 7.39 (m, 3H), 7.48 (m, 3H), 7.54 (t, *J* = 8 Hz, 1H), 11.44 (s, 1H). ¹³CNMR (125 MHz, CDCl₃): δ 13.68, 61.32, 116.80, 119.49, 122.91, 126.14, 127.59, 128.33, 128.78, 128.84, 131.53, 134.64, 138.41, 150.62, 161.09, 165.55. HRMS (EI): *m/z* Calcd. For C₁₈H₁₅NO₃: 293.1052, Found: 293.1054.

4-(4-Methoxyphenyl)-2-oxo-1,2-dihydroquinoline-3-carboxylic Acid Ethyl Ester 16b. ¹HNMR (CDCl₃): δ 1.04 (t, *J* = 6 Hz, 3H), 3.88 (s, 3H), 4.16 (m, 2H), 7.01 (d, *J* = 10 Hz, 2H), 7.14 (t, *J* = 7 Hz, 1H), 7.34 (m, 3H), 7.40 (d, *J* = 8 Hz, 1H), 7.53 (t, *J* = 7 Hz, 1H), 11.63 (s, 1H). ¹³CNMR (125 MHz, CDCl₃): δ 13.85, 55.34, 61.31, 113.80, 116.66, 119.78, 122.81, 126.76, 127.63, 130.18, 131.40, 138.36, 160.05, 161.01, 165.77. HRMS (EI): *m/z* Calcd. For C₁₉H₁₇NO₄: 323.1158, Found: 323.1157.

4-(3-Cyanophenyl)-2-oxo-1,2-dihydroquinoline-3-carboxylic Acid Ethyl Ester 16c. ¹HNMR (CDCl₃): δ 1.05 (t, J = 7 Hz, 3H), 4.16 (m, 2H), 7.12 (d, J = 7 Hz, 1H), 7.18 (t, J = 7 Hz, 1H), 7.50 (d, J = 8 Hz, 1H), 7.57 (t, J = 7 Hz, 1H), 7.64 (m, 2H), 7.71(s, 1H), 7.81 (m, 1H), 12.43 (s, 1H). ¹³CNMR (125 MHz, CDCl₃): δ 13.81, 61.62, 112.86, 117.04, 117.95, 118.69, 123.35, 126.64, 126.85, 129.43, 132.05, 132.24, 132.50, 133.22, 135.96, 138.47, 147.84, 160.73, 164.90. HRMS (EI): *m/z* Calcd. For C₁₉H₁₄N₂O₃: 318.1004. Found: 318.1001.

4-Allyl-2-oxo-1,2-dihydroquinoline-3-carboxylic Acid Ethyl Ester 16d. ¹HNMR (CDCl₃): δ 1.43 (m, 3H), 3.64 (d, *J* = 7 Hz, 2H), 4.46 (m, 2H), 5.17 (t, *J* = 10 Hz, 2H), 5.97 (m, 1H), 7.24 (d, *J* = 9 Hz, 1H), 7.28 (s, 1H), 7.53 (t, *J* = 7 Hz, 1H), 7.76 (d, *J* = 9 Hz, 1H), 10.63 (d, *J* = 5 Hz, 1H). ¹³CNMR (125 MHz, CDCl₃): δ 14.23, 34.19, 61.70, 117.14, 117.96, 118.68, 122.88, 125.41, 126.52, 131.27, 133.63, 138.35, 147.36, 161.30, 166.35. HRMS (EI): *m/z* Calcd. For C₁₅H₁₅NO₃: 257.1052. Found: 257.1054.

2-Oxo-4-phenylethynyl-1,2-dihydroquinoline-3-carboxylic Acid Ethyl Ester 16e. A mixture of 4-chloro quinolinone 14 (100 mg, 0.4 mmol), K_2CO_3 (82 mg, 0.6 mmol), $Pd(OAc)_2$ (10 mg, 0.04 mmol), PPh₃ (42 mg, 0.16 mmol), CuI (8 mg, 0.04 mmol) and phenylacetylene 15e (61 mg, 0.6 mmol) in 10 mL acetonitrile was refluxed under nitrogen for 4 h, monitored by TLC, the solvent was evaporated in vacuo and the crude product was purified by column chromatography (ethyl acetate/petroleum ether = 1:1).

¹HNMR (CDCl₃): δ 1.44 (t, *J* = 7 Hz, 3H), 4.52 (m, 2H), 7.34 (m, 2H), 7.44 (t, *J* = 7 Hz, 3H), 7.61 (m, 3H), 8.11 (d, *J* = 9 Hz, 1H), 11.39 (s, 1H). ¹³CNMR (100 MHz, CDCl₃): δ 14.33, 61.92, 82.14, 103.84, 111.89, 116.67, 118.72, 121.57, 123.33, 127.17,

128.64, 129.96, 132.01, 132.06, 132.49, 138.19, 160.64, 165.20. HRMS (EI): m/z Calcd. For $C_{20}H_{15}NO_3$: 317.1052. Found: 317.1052.

2-Oxo-4-trimethylsilanylethynyl-1,2-dihydroquinoline-3carboxylic Acid Ethyl Ester 16f. A 25 mL sealed steel reactor was charged with a mixture of 4-chloro quinolinone 14 (200 mg, 0.8 mmol), K_2CO_3 (164 mg, 0.6 mmol), $Pd(OAc)_2$ (36 mg, 0.16 mmol), PPh₃ (170 mg, 0.64 mmol), CuI (30 mg, 0.16 mmol), trimethylsilylacetylene 15f (23 mg, 2.4 mmol) in 25 mL toluene. The system was heated at 100 °C under nitrogen for 20 h, monitored by TLC, the solvent was evaporated in vacuo and the crude product was purified by column chromatography (ethyl acetate/petroleum ether = 1:3).

¹HNMR (CDCl₃): δ 0.32 (s, 3H), 1.45 (t, J = 5 Hz, 3H), 4.48 (m, 2H), 7.28 (t, J = 10 Hz, 1H), 7.37 (t, J = 7 Hz, 1H), 7.57 (m, 1H), 7.99 (d, J = 5 Hz, 1H), 11.97 (s, 1H). ¹³CNMR (100 MHz, CDCl₃): δ 0.00, 14.60, 62.28, 97.10, 111.48, 117.07, 119.06, 123.78, 127.57, 129.91, 130.10, 132.37, 138.55, 161.05, 165.40. HRMS (ESI): m/z Calcd. For C₁₇H₁₉NNaO₃Si [M + Na]⁺: 336.1026, Found: 336.1053.

Acknowledgments. The authos gratefully acknowledge the financial support for Shanghai Municipal Natural Science Foundation (10ZR1409600) and the Fundamental Research Funds for the Central Universities. The authos also thank Lab of Organic Functional Molecules, the Sino-French Institute of ECNU for supports.

REFERENCES AND NOTES

[1] For the representative references see; (a) Frazier, K.; Jazan, E.; McBride, C. M.; Pecchi, S.; Renhowe, P. A.; Shafer, C. M.; Taylor, C.; Bussiere, D.; He, M. M.; Jansen, J. M.; Lapointe, G.; Ma, S.; Vora, J.; Wiesmann, M. Bioorg Med Chem Lett 2006, 16, 2247; (b) Fraley, M. E.; Arrington, K. L.; Buser, C. A.; Ciecko, P. A.; Coll, K. E.; Fernandes, C.; Hartman, G. D.; Hoffman, W. F.; Lynch, J. J.; McFall, R. C.; Rickert, K.; Singh, R.; Smith, S.; Thomas, K. A.; Wong, B. K. Bioorg Med Chem Lett 2004, 14, 351; (c) Cappelli, A.; Giuliani, G.; Anzini, M.; Riitano, D.; Giorgi, G.; Vomero, S. Bioorg Med Chem 2008, 16, 6850; (d) Renhowe, P. A.; Pecchi, S.; Machajewski, T. D.; Shafer, C. M.; Taylor, C.; McCrea Jr, W. R.; McBride, C.; Jazan, E. U.S. Patent 6774237, 2004. (e) Hewawasam, P.; Fan, W.; Ding, M.; Flint, K.; Cook, D.; Goggins, G. D.; Myers, R. A.; Gribkoff, V. K.; Boissard, C. G.; Dwo, J. R.; Lodge, N. J. J Med Chem 2003, 46, 2819.

[2] Bonnefous, C.; Payne, J. E.; Roppe, J.; Zhuang, H.; Chen, X. H.; Symons, K. T.; Nguyen, P. M.; Sablad, M.; Rozenkrants, N.; Zhang, Y.; Wang, L.; Severance, D.; Walsh, J. P.; Yazdani, N.; Shiau, A. K.; Noble, S. A.; Rix, P.; Rao, T. S.; Hassig, C. A.; Smith, N. D. J Med Chem 2009, 52, 3047.

[3] Claassen, G.; Brin, E.; Crogan-Grundy, C.; Vaillancourt, M. T.; Zhang, H. Z.; Cai, S. X.; Drewe, J.; Tseng, B.; Kasibhatla, S. Cancer Lett 2009, 274, 243.

[4] Wall, M. J.; Chen, J. S.; Meegalla, S.; Ballentine, S. K.; Wilson, K. J.; DesJarlais, R. L.; Schubert, C.; Chaikin, M. A.; Crysler, C.; Petrounia, I. P.; Donatelli, R. R.; Yurkow, E. J.; Boczon, L.; Mazzulla, M.; Player, M. R.; Patch, R. J.; Manthey, C. L.; Molloy, C.; Tomczuk, B.; Illig, C. R. Bioorg Med Chem Lett 2008, 18, 2097.

[5] (a) Peifer, C.; Kinkel, K.; Abadleh, M.; Schollmeyer, D.; Laufer
S. J Med Chem 2007, 50, 1213. (b) Park, K. K.; Lee, J. J. Tetrahedron
2004, 60, 2993. (c) Koltunov, K. Y.; Walspurger, S.; Sommer, J. Eur
J Org Chem 2004, 4039. (d) Inamoto, K.; Saito, T.; Hiroya, K.; Doi, T.
J Org Chem 2010, 75, 3900.

[6] Rowley, M.; Leeson, P. D.; Stevenson, G. I.; Moseley, A. M.; Stansfield, I.; Sanderson, I.; Robinson, L.; Baker, R.; Kemp, J. A.; Marshall, G. R.; Foster, A. C.; Grimwood, S.; Tricklebank, M. D.; Saywell, K. L. J Med Chem 1993, 36, 3386.

[7] Ukrainets, I. V.; Gorokhova, O. V.; Sidorenko, L. V. Chem Heterocycl Comp 2005, 41, 1019.